EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Navigating relapsed hepatoblastoma: Predictive factors and surgical treatment strategy

Andres F Espinoza iD, Kalyani R Patel, Priya B Shetty, Richard S Whitlock iD, Pavel Sumazin, Xinjian Yu, Stephen F Sarabia iD, Martin Urbicain, Andras Heczey, Prakash Masand, Sarah E Woodfield, Dolores H López-Terrada und 1 weitere

Cancer Medicine · 2023-12 · 12 (23) · 21270-21278

DOI: 10.1002/cam4.6705 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Medicine, online erschienen am 14.11.2023. Verfasst von Andres F Espinoza und 12 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pediatric Surgery, Michael E. DeBakey Department of Surgery, Texas Children's Surgical Oncology Program and Liver Tumor Program, Dan L. D…. Hauptthemen laut MEDLINE: Hepatoblastoma, Liver Neoplasms. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, Macy Easom Cancer Research Foundation, National Cancer Institute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Hepatoblastoma (HB) is the most common primary hepatic malignancy in childhood. Relapse occurs in more than 50% of high‐risk patients with a high mortality due to ineffective salvage therapies. The purpose of this study is to identify risk factors for relapsed HB and predictors of survival in a single tertiary referral center.

Methods

A retrospective chart review showed 129 surgically treated HB patients from October 2004 to July 2020. Of the cohort, 22 patients presented with relapsed HB. Relapse was defined as re‐appearance of malignancy after 4 weeks of normalized AFP and disappearance of all tumors on imaging.

Results

Patients with relapsed HB had a 5‐year overall survival (OS) of 45.4% compared to 93.1% in those without relapse ( p = 0.001). When comparing PRETEXT IV, microvascular invasion, metastatic disease, and age on multivariate logistic regression, only PRETEXT IV was an independent risk factor for relapsed HB with an OR of 2.39 (95% CI: 1.16–4.96; p = 0.019). Mixed epithelial and mesenchymal HB (12/19, 63.2%) was the most common histology of primary tumors while pure epithelial HB (13/15, 86.6%) was the most common relapsed histology. Combination of surgical and medical therapy for relapsed disease was predictive of survival with an HR of 16.3 (95% CI: 1.783–149.091; p = 0.013) compared to only chemotherapy.

Conclusions

This study demonstrates that PRETEXT IV staging is an independent predictor of relapsed disease. The most common relapsed histology was epithelial, suggesting a potential selection or resistance of this component. Surgical resection is a critical component of multimodal therapy for relapsed HB.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HepatoblastomaLiver NeoplasmsHumansInfantRetrospective StudiesPrognosisRecurrenceTreatment Outcome

Stichwörter der Autor:innen

hepatoblastomapatient-derived xenograftrelapse

Autor:innen und Institutionen

  • Division of Pediatric Surgery, Michael E. DeBakey Department of Surgery, Texas Children's Surgical Oncology Program and Liver Tumor Program, Dan L. Duncan Cancer Center, Baylor College of Medicine, Houston, Texas, USA.
  • Department of Pathology and Immunology, Texas Children's Hospital, Baylor College of Medicine, Houston, Texas, USA.
  • Department of Pediatric Hematology and Oncology, Texas Children's Hospital, Baylor College of Medicine, Houston, Texas, USA.
  • Singleton Department of Pediatric Radiology, Texas Children's Hospital, Baylor College of Medicine, Houston, Texas, USA.

ORCID-Profile: Andres F Espinoza, Richard S Whitlock, Stephen F Sarabia

Förderung

  • NCI NIH HHS
  • Macy Easom Cancer Research Foundation
  • National Cancer Institute

Zitieren

APA

Espinoza, A. F., Patel, K. R., Shetty, P. B., Whitlock, R. S., Sumazin, P., Yu, X., Sarabia, S. F., Urbicain, M., Heczey, A., Masand, P., Woodfield, S. E., López-Terrada, D. H., & Vasudevan, S. A. (2023). Navigating relapsed hepatoblastoma: Predictive factors and surgical treatment strategy. Cancer Medicine, 12(23), 21270-21278. https://doi.org/10.1002/cam4.6705

Vancouver

Espinoza AF, Patel KR, Shetty PB, Whitlock RS, Sumazin P, Yu X, et al. Navigating relapsed hepatoblastoma: Predictive factors and surgical treatment strategy. Cancer Medicine. 2023;12(23):21270-21278. doi:10.1002/cam4.6705

BibTeX
@article{Espinoza2023,
  author = {Espinoza, Andres F and Patel, Kalyani R and Shetty, Priya B and Whitlock, Richard S and Sumazin, Pavel and Yu, Xinjian and Sarabia, Stephen F and Urbicain, Martin and Heczey, Andras and Masand, Prakash and Woodfield, Sarah E and López-Terrada, Dolores H and Vasudevan, Sanjeev A},
  title = {Navigating relapsed hepatoblastoma: Predictive factors and surgical treatment strategy},
  journal = {Cancer Medicine},
  year = {2023},
  volume = {12},
  number = {23},
  pages = {21270--21278},
  doi = {10.1002/cam4.6705}
}
Kostenlos starten →